Henry Koo
Impact in
-
- Growth Hormone and Insulin-like Growth Factors
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Monoclonal and Polyclonal Antibodies Research 3
- Oncology 3
- Vascular Tumors and Angiosarcomas 2
- HER2/EGFR in Cancer Research 1
- Co-authors
- Dale L. LudwigPeter BöhlenDaniel J. HicklinRajiv BassiXenia JimenezPaul KussieZhenping ZhuLarry Witte
- Journals
- Leukemia (1 paper)Clinical Cancer Research (1 paper)Protein Expression and Purification (1 paper)Journal of Biological Chemistry (1 paper)Cancer Research (1 paper)
- Partner nations
- United States
In The Last Decade
Henry Koo
6 papers receiving 686 citations
Peers
Comparison fields: 5 of 67
- Endocrinology, Diabetes and Metabolism 216
- Cancer Research 186
- Oncology 237
- Molecular Biology 538
- Radiology, Nuclear Medicine and Imaging 156
Countries citing papers authored by Henry Koo
This map shows the geographic impact of Henry Koo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry Koo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry Koo more than expected).
Fields of papers citing papers by Henry Koo
This network shows the impact of papers produced by Henry Koo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry Koo. The network helps show where Henry Koo may publish in the future.
Co-authors
The 25 scholars most cited alongside Henry Koo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2006 | 120 | |
| 2 | 2005 | 146 | |
| 3 | A fully human monoclonal antibody against VEGFR-1 inhibits growth of human breast cancers | 2004 | 1 |
| 4 | 2003 | 131 | |
| 5 | A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. | 2003 | 298 |
| 6 | 2002 | 35 |
About Henry Koo
Henry Koo is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Molecular Biology, Cell Biology and Endocrinology, Diabetes and Metabolism, having authored 6 papers that have together received 731 indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (3 papers), Glycosylation and Glycoproteins Research (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Vascular Tumors and Angiosarcomas (2 papers), HER2/EGFR in Cancer Research (1 paper), Chemotherapy-induced cardiotoxicity and mitigation (1 paper), Proteoglycans and glycosaminoglycans research (1 paper) and Growth Hormone and Insulin-like Growth Factors (1 paper). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (216 citations), Cancer Research (186 citations), Oncology (237 citations), Molecular Biology (538 citations) and Radiology, Nuclear Medicine and Imaging (156 citations). Henry Koo has collaborated with scholars based in United States. Frequent co-authors include Dale L. Ludwig, Peter Böhlen, Daniel J. Hicklin, Rajiv Bassi, Xenia Jimenez, Paul Kussie, Zhenping Zhu, Larry Witte, Marie Prewett and Dan Lu. Their work appears in journals such as Leukemia, Clinical Cancer Research, Protein Expression and Purification, Journal of Biological Chemistry and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.